EP1517997A4 - Luminogene proteasesubstrate - Google Patents

Luminogene proteasesubstrate

Info

Publication number
EP1517997A4
EP1517997A4 EP03729139A EP03729139A EP1517997A4 EP 1517997 A4 EP1517997 A4 EP 1517997A4 EP 03729139 A EP03729139 A EP 03729139A EP 03729139 A EP03729139 A EP 03729139A EP 1517997 A4 EP1517997 A4 EP 1517997A4
Authority
EP
European Patent Office
Prior art keywords
substrate
protease
seq
enzyme
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03729139A
Other languages
English (en)
French (fr)
Other versions
EP1517997A2 (de
Inventor
Zhenjun Diwu
Jinfang Liao
Zhiqiang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Devices LLC
Original Assignee
Molecular Devices LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Devices LLC filed Critical Molecular Devices LLC
Publication of EP1517997A2 publication Critical patent/EP1517997A2/de
Publication of EP1517997A4 publication Critical patent/EP1517997A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Definitions

  • the invention relates to enzyme assays, and more particularly to protease assays using luminogenic protease substrates that include a rhodamine-based luminophore.
  • proteases include a number of families of proteolytic enzymes that are capable of catalytically hydrolyzing peptide bonds. Principal groups of proteases include metalloproteases, serine proteases, cysteine proteases, and aspartic proteases. Proteases, in particular serine proteases, are involved in a number of physiological processes, such as blood coagulation, fertilization, inflammation, hormone production, the immune response, and fibrinolysis.
  • Numerous disease states are caused by and/or can be characterized by alterations in the activity of specific proteases and/or their inhibitors. Therefore, the measurement of these alterations is often clinically significant in the treatment and management of the underlying disease states. For example, emphysema, arthritis, thrombosis, cancer metastasis, and some forms of hemophilia result from the lack of regulation of serine protease activities (see, for example, Textbook of Biochemistry with Clinical Correlations, John Wiley and Sons, Inc. New York, 1993).
  • Viral proteases have been identified in cells suffering from viral infections.
  • Such viral proteases can include, for example, HIV protease, typically associated with AIDS, and/or NS3 protease, typically associated with Hepatitis C. These viral proteases may play a critical role in the life cycle of the infecting virus.
  • Certain proteases have also been implicated in cancer metastasis. Increased synthesis of the protease urokinase has been correlated with an increased ability to metastasize in many cancers. Urokinase acts on plasminogen to generate plasmin, which in turn can cause the degradation of the proteins in the extracellular matrix through which the metastasizing tumor cells invade. Plasmin can also activate collagenases, thus promoting the degradation of the collagen in the basement membrane surrounding the capillaries and lymph system, also allowing tumor cells to invade into target tissues (see for example, Dano et al. Adv. Cancer. Res. 44, 139, 1985). The ability to measure changes in the activity of specific proteases may be clinically significant in the treatment and management of many underlying disease states.
  • protease assays have generally proven difficult to assay. Typical approaches may include ELISA assays (Enzyme-Linked ImmunoSorbent Assay), which use labeled antibodies that bind the protease enzyme, and RIA assays (Radioimmunoassays), which use various radioactive-labeled substrates.
  • ELISA assays Enzyme-Linked ImmunoSorbent Assay
  • RIA assays Radioimmunoassays
  • protease detection has employed chromogenic and/or luminogenic protease substrates (i.e., substrates that exhibit a change in, or the occurrence of, color or luminescence when cleaved by protease activity).
  • substrates typically rely upon a cleavage-induced change in the structure of a chromophore or luminophore that changes the spectroscopic properties of the chromophore or luminophore.
  • amino-substituted fluorophores have been used to prepare enzyme substrates featuring a peptide side chain bound via an amide linkage. Protease-mediated cleavage of the amide regenerates the free fluorophore (see Scheme 1 below).
  • Luminogenic substrates generally are preferred over chromogenic substrates because luminescence-based assays generally are more sensitive than colorimetric assays.
  • Coumarin-based and rhodamine 110-based fluorogenic substrates may be used to determine protease activities.
  • coumarin-based substrates exhibit low extinction coefficients that limit their utility.
  • the autofluorescence exhibited by most biological samples generally leads to high background noise, particularly in microscopic assays, due to the short excitation and emission wavelengths of the coumarin cleavage products. These features seriously limit the assay sensitivity of coumarin-based protease substrates (See, A. Keppler-Hafkemeyer, U.
  • Protease substrates that incorporate a rhodamine 110 fluorophore may be used (see U.S. Patent Nos. 4,557,862 and 4,640,893, both to Mangel et al.) to help overcome the limitations associated with coumarin-based protease substrates.
  • the resulting bis-peptide-substituted rhodamine compounds also exhibit significant drawbacks.
  • the rhodamine-based substrates feature two protease-cleavable peptide residues, requiring multiple independent hydrolytic steps to yield the free fluorophore.
  • the intermediate product of the first hydrolysis is significantly less fluorescent than the free fluorophore (see Scheme 2).
  • monopeptide rhodamine 110-based protease substrates may exhibit a poor enzyme turnover rate, and altered cellular localization profiles, in addition to their reduced sensitivities.
  • compositions suitable for performing enzyme assays, such as protease assays.
  • the compositions may include derivatives of rhodamine 110 that are substituted at the xanthylium nitrogens by a peptide moiety and a morpholine-4-carbonyl moiety, respectively. These compositions may be luminogenic substrates for a large variety of protease enzymes, with utility in a variety of sensitive protease enzyme assays.
  • Figure 3 is a graph showing the fluorescence emission spectrum of a sample containing Compound 9 before (bottom curve) and after (top curve) the addition of caspase-3, a protease enzyme involved in apoptosis.
  • Figure 4 is a graph showing the time-dependent increase in fluorescence intensity of Compound 9 upon addition of caspase-3, as described in Example 21.
  • Figure 5 is a graph demonstrating the significantly higher enzyme turnover rate exhibited by Compound 9 (Ac-DEND-Rhl lO-MPL) (curve A) relative to (Ac- DEVD) 2 Rhl 10 (curve B), as described in Example 22.
  • Figure 6 is a chart demonstrating the detection of caspase-3 activity related to apoptosis using Compound 9, as described in Example 23.
  • Figure 7 is a chart demonstrating the cell number response of detected caspase-3 activity in JurKat cells using Compound 9, as described in Example 24.
  • Figure 8 is a chart demonstrating the dose response of camptothecin on JurKat cell apoptosis measured using Compound 9, as described in Example 24.
  • Figure 9 is a chart showing the time course response of detected camptothecin- induced JurKat cell apoptosis measured using Compound 9, as described in Example 24.
  • Figure 10 is a chart showing the higher sensitivity of Compound 9 relative to to (Ac-DEND) 2 Rhl l0 for detection of human recombinant caspase-3 activity in whole cells , as described in Example 25.
  • Figures 11-13 are reaction schemes showing a synthetic pathway for a stepwise synthesis of Ac-DEND-Rhl lO-MPL (Compound 9), as described in Examples 1-9.
  • Figure 14 is a reaction scheme showing a synthetic pathway for a two-step synthesis of Ac-DEND-Rhl 10-MPL (Compound 9).
  • the invention provides systems, including compositions, kits, and methods, suitable for performing protease assays.
  • the compounds of the invention may be useful as luminogenic protease enzyme substrates.
  • the compounds may be used to detect protease activity in a sample.
  • the compounds of the present invention generally comprise a peptide linked to rhodamine moiety through a xanthylium amine group, and a morpholine moiety linked to the rhodamine through the remaining xanthylium amine group.
  • the particular rhodamine may be selected so as to provide one or more desired spectral or other properties.
  • the particular peptide alternatively or additionally may be selected so that it is recognized and cleaved by a particular protease.
  • the compounds of the invention may include protease substrates generally described by the formula:
  • R 1 is a covalently bound moiety that, upon cleavage by an appropriate enzyme, generates a luminescent rhodamine-based reaction product having the formula:
  • Substituent R 1 typically is a monovalent radical that may be formally derived by the removal of a hydroxyl from a carboxylic acid functional group on an amino acid, or from a carboxylic acid of an amino acid of a peptide.
  • the carboxylic acid functional group may be the terminal carboxylic acid of the peptide chain (the C- terminus).
  • the peptide may be a linear or branched peptide.
  • R 1 includes more than one amino acid
  • R 1 may be a peptide radical having less than about 50 amino acids, and more typically less than about 30 amino acids.
  • R 1 may be a peptide radical having 1-4 amino acids.
  • R 1 may include 2 to about 12 amino acids, 2 to about 10 amino acids, 2 to about 8 amino acids, 2 to about 6 amino acids, or 2 to about 4 amino acids, among others.
  • Substituents R 2 -R 5 are independently hydrogen, halogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, sulfonic acid, or carboxylic acid.
  • sulfonic acid and “carboxylic acid” may include the protonated functional group, the deprotonated and ionic functional group, and salts of the functional group.
  • the carboxylic acid or sulfonic acid functional group may be "masked” or protected so as to render the resulting compound more cell-permeable.
  • protecting groups include esters of alcohols having 1-6 carbons or esters of acyloxyalkyl groups, preferably acetoxymethyl esters.
  • R 2 -R 5 may be -L-R x or -L-Sc, where Rx is a reactive functional group, Sc is a conjugated substance, and L is a covalent linking moiety.
  • Rx is a reactive functional group
  • Sc is a conjugated substance
  • L is a covalent linking moiety.
  • At least two of substituents R 2 -R 5 may be halogen substituents.
  • at least two of R 2 -R 5 may be chloro substituents.
  • at least two of R 2 -R 5 maybe fluoro substituents.
  • R -R typically is one or the other of R and R 4 .
  • Derivatives of the dyes that are 5- or 6-carboxy derivatives or that are prepared from the 5- or 6-carboxy derivatives are generally more readily available, both commercially and due to their relative ease of synthesis.
  • the compounds of the invention may be present as a mixture of 5- and 6-carboxy isomers or their derivatives, methods are available, including high-resolution chromatographic methods, for separating the 5- and 6-substituted isomers of the compounds of the invention, according to methods known in the art.
  • R 1 is, or is derived from, an amino acid
  • the amino acid may be a natural or synthetic amino acid, optionally modified on any free amine or carboxylic acid by a suitable protecting group.
  • suitable amine protecting groups include carbobenzyloxy (CBZ), 9-fluorenylmethyl carbamate (Fmoc), p-toluenesulfonyl (tosyl), succinoyl, glutaroyl, acetyl or other protecting groups that yield the corresponding amide.
  • the other functional groups present on the amino acid may be modified by esterif ⁇ cation or alkylation.
  • Suitable protecting groups for peptide synthesis, among others, are provided in Table 1.
  • Table 1 Selected protecting groups useful for peptide synthesis.
  • R is, or is derived from, a peptide or polypeptide
  • the peptide or polypeptide may incorporate natural or synthetic amino acids, each of which may be modified on any free amine or carboxylic acid by a suitable protecting group, as described above.
  • “Peptides” and “polypeptides”, as used herein, include chains of amino acids whose ⁇ -carbons are linked through peptide bonds typically formed by a condensation reaction between the ⁇ -carboxyl group of one amino acid and the amino group of another amino acid. The terminal amino acid at one end of the chain (amino terminal) therefore has a free amino group, while the terminal amino acid at the other end of the chain (carboxy terminal) has a free carboxyl group.
  • amino terminus refers to the free -amino group on an amino acid at the amino terminal of a peptide or to the ⁇ -amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the peptide.
  • carboxy terminus refers to the free carboxyl group on the carboxy terminus of a peptide or the carboxyl group of an amino acid at any other location within the peptide.
  • Peptides also include peptide mimetics such as amino acids joined by an ether as opposed to an amide bond.
  • polypeptides described herein may be written with the amino terminus at the left and the carboxyl terminus at the right.
  • the amino acids comprising the peptide components of this invention are numbered with respect to the protease cleavage site, with numbers increasing consecutively with distance in both the carboxyl and amino direction from the cleavage site.
  • the term "residue” or "amino acid” as used herein refers to an amino acid that is incorporated into a peptide.
  • the amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass known analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.
  • domain may refer to a characteristic region of a polypeptide.
  • the domain may be characterized by a particular structural feature, such as a ⁇ -turn, an ⁇ -helix, or a ⁇ -pleated sheet, by characteristic constituent amino acids (e.g., predominantly hydrophobic or hydrophilic amino acids, or repeating amino acid sequences), or by its localization in a particular region of the folded three dimensional polypeptide.
  • a region or domain is composed of a series of contiguous amino acids.
  • R 1 may be derived from a peptide having a sequence suitable for cleavage by the desired enzyme.
  • R 1 is selected so that the resulting compound is a binding site and substrate for a protease enzyme (also known as a peptidase enzyme).
  • Suitable enzymes include, without limitation, aminopeptidases and dipeptidyl peptidases, such as dipeptidyl peptidases I, II and IV, calpain, elastase, trypsin, chymotrypsin, granzyme A, thrombin, cathepsins, urokinase, kallikrein, human adenovirus proteinase, plasminogen activator, interleukin converting enzyme, amyloid A4- generating enzyme, follipsin and leucine aminopeptidase.
  • R 1 may be selected so that the resulting compound is a caspase enzyme substrate.
  • protease activity typically refers to the cleavage of a substrate peptide by a protease enzyme.
  • protease activity may comprise the "digestion” of one or more peptides into a large number of smaller peptide fragments.
  • protease activity of particular proteases may result in hydrolysis at particular peptide binding sites characteristically recognized by that particular protease.
  • the particular protease may be characterized by the production of peptide fragments bearing particular terminal amino acid residues.
  • amino acids or peptides referred to herein may be described in part using shorthand designations, as shown in Table 2.
  • Other abbreviations that may be used herein include “Fmoc” for 9-fluorenylmethyoxycarbonyl, "Ac” for acetyl, “Boc” for tert-butoxycarbonyl, “Z” or “Cbz” for benzyloxycarbonyl, “MPL” for morpholinecarbonyl, "AA” for amino acids, "PP” for peptides, and “Rhl lO” for rhodamine 110.
  • a peptidyl-rhodamine 110-morpholinecarbonyl compound of the invention may be referred to using these shorthand designations as '(PP)-Rhl lO-MPL'.
  • the compounds of the invention may include, among others, polypeptides that include the sequences listed in Table 3.
  • the amino acid residues that comprise a protease binding site may be numbered relative to the peptide bond hydrolyzed by a particular protease. Therefore, as used below, the first amino acid residue on the amino side of the cleaved peptide bond is designated PI. The numbering of the residues increases with distance away from the hydrolyzed peptide bond.
  • Table 3 Selected particular peptide sequences.
  • one or more of the rhodamine substituents R -R may be a reactive functional group (R x ) or a conjugated substance (Sc) that is bound to the compound of the invention by a covalent linkage, L.
  • Covalent linkage L may be a single covalent bond, or L may incorporate a series of nonhydrogen atoms that form a stable linkage between the reactive functional group or conjugated substance and the compound. Typically, L incorporates 1-20 nonhydrogen atoms in a stable conformation.
  • Stable atom conformations include, without limitation, carbon-carbon bonds, amide linkages, ester linkages, sulfonamide linkages, ether linkages, thioether linkages, and other covalent bonds well-known in the art.
  • Preferred covalent linkages are single bonds, carboxamides, sulfonamides, ethers, and carbon-carbon bonds, or a combination thereof.
  • Any reactive functional group that exhibits appropriate reactivity to cross- react and conjugate with a desired substance is a suitable reactive functional group for the purposes of the invention.
  • the choice of the reactive group used typically depends on the functional groups present on the substance to be conjugated.
  • functional groups present on such substances include, but are not limited to, alcohols, aldehydes, amines, carboxylic acids, halogens, ketones, phenols, phosphates, and thiols, or a combination thereof.
  • Rx groups include activated esters of carboxylic acids, aldehydes, alkyl halides, amines, anhydrides, aryl halides, carboxylic acids, haloacetamides, halotriazines, hydrazines (including hydrazides), isocyanates, isothiocyanates, maleimides, phosphoramidites, sulfonyl halides, and thiol groups, or a combination thereof.
  • Rx is an activated ester of a carboxylic acid, an amine, a haloacetamide, a hydrazine, an isothiocyanate, or a maleimide group.
  • Rx is a succinimidyl ester of a carboxylic acid.
  • the compounds of the invention that have a covalently bound reactive functional group may be used to prepare a variety of conjugates.
  • the conjugated substance is a member of a specific binding pair.
  • the conjugated substance is a molecular carrier.
  • the conjugated substance is a biomolecule that is an amino acid, a peptide, a protein, a nucleoside, a nucleotide, an oligonucleotide, a nucleic acid polymer, or a carbohydrate.
  • Selected conjugated substances may aid the retention of the protease substrates within cell membranes, localize the protease substrates within a selected region of a cell, or bind the luminescent enzymatic cleavage product to a preselected component of a sample under investigation.
  • the conjugated substance is a polar moiety, or a masked polar moiety.
  • the conjugated substance is a solid or semi-solid matrix.
  • the conjugated substance Sc is an amino acid, a peptide, a protein, a nucleoside, a nucleotide, an oligonucleotide, a nucleic acid polymer, or a carbohydrate
  • the conjugated substance may be a naturally occurring or a synthetically modified substance.
  • the conjugated substance also may be a member of a specific binding pair or a molecular carrier. Specific binding pair members typically specifically bind to and are complementary with the complementary member of the specific binding pair. Conjugated members of a specific binding pair typically are used to localize the compound of the invention to the complementary member of that specific binding pair. Representative specific binding pairs are listed in Table 4.
  • Table 4 Representative specific binding pair members.
  • conjugated substance Sc is a carrier
  • it typically is a biological or artificial polymer.
  • Biological polymers include proteins, carbohydrates, and nucleic acid polymers.
  • Artificial polymers include polyethylene glycols and polymeric microparticles composed of polystyrene, latex, or other polymeric material.
  • a conjugated carrier is a carbohydrate that is a dextran, or amino- substituted dextran, or a polymeric microparticle.
  • Such carriers are useful for altering the solubility of the compound, enhancing its retention within cell membranes, or decreasing its compartmentalization within cells.
  • the conjugated substance is typically substituted one or more times by a highly polar functional group, such as a carboxylic acid or sulfonic acid.
  • a highly polar functional group such as a carboxylic acid or sulfonic acid.
  • the polar moiety typically is masked or protected, temporarily rendering it more lipophilic and therefore more cell-permeant.
  • One such masking group is an ester group that may be cleaved by esterases to release the free polar moiety within cell membranes, where they are well-retained.
  • the polar moiety is a carboxylic acid, a dicarboxylic acid, or a tricarboxylic acid moiety that is protected as an ester, such as an acetoxymethyl ester.
  • the conjugated substance may be a metal or glass surface, and may be, for example, the sides or bottom of a microwell, or a slide, or the surface of a chip.
  • Conjugation of an appropriate luminogenic protease substrate to the interior surfaces of the wells on a multi-well microplate may generate a preassembled assay system for selected protease activity, requiring only the addition of sample solutions and/or appropriate control solutions to perform a selected assay.
  • Selected buffers and/or other reagents may also be provided as dry components within the microplate wells, further facilitating the formulation of a microplate assay kit for protease activity. Such a kit would have particular utility for high-throughput assays.
  • the compounds of the invention are converted by protease enzymes to a highly luminescent enzymatic product in a single step, as shown below in Scheme 3.
  • the instant substrates are more sensitive than the corresponding bis-peptide rhodamine derivatives, and, unlike existing lipophilic monopeptide-substituted rhodamine compounds, the enzymatic product 'Rhl lO-(morpholine amide)' is as fluorescent as free rhodamine 110 (the enzymatic product of the bis-peptide rhodamine substrates. Additionally, the instant substrates are better retained in cells than free rhodamine 110.
  • the instant protease substrates exhibit a high luminescence signal upon cleavage, but a very low luminescence signal in their spirolactone form. Further, appropriate selection of peptide sequence may result in substrates that exhibit a high degree of protease specificity.
  • the luminescence signal of the cleavage product typically occurs in the visible region, well-separated from cellular autofluorescence, thereby rendering them highly suitable for use in biological samples.
  • the compounds of the invention may be used in combination with simple solutions of protease enzymes, or they may be used to stain samples that contain cells.
  • the sample typically is stained by passive means, i.e., by incubation of the desired sample with a staining solution containing the selected compound of the invention. Passive incubation is most useful for compounds of the invention that have been masked or protected and that therefore are nonpolar and cell-permeable.
  • any other suitable method of introducing the compound of the invention into the sample such as microinjection, can be used to aid or accelerate introduction of the dye into the sample.
  • a staining solution of the compound of the invention is prepared.
  • the compound of the invention typically may first be dissolved in an organic solvent, such as DMSO or DMF, to prepare a concentrated stock solution.
  • the stock solution may then be diluted into the appropriate aqueous solution, typically a buffer solution, to prepare the staining solution for addition to the sample.
  • the nonfluorescent spirolactone compounds of the invention are typically less soluble in aqueous solutions than the free fluorescent products of protease activity.
  • the compound of the invention may be suspended in a semi-solid matrix, such as a polymer gel, for addition to tissue sections and other solid samples.
  • the sample is optionally combined with other solutions in the course of staining, such as wash solutions or solutions containing additional detection reagents.
  • An additional detection reagent is a reagent that produces a detectable response due to the presence of a specific cell component, intracellular substance, or cellular condition, according to methods generally known in the art. Where the additional detection reagent has spectral properties that differ from those of the subject substrates, multi-color applications are possible.
  • the sample is incubated for a time sufficient for any protease enzymes in the sample to cleave the peptide region and convert the spirolactone form of the dye to the free form of the dye.
  • the sample may be illuminated and the resulting optical signal detected.
  • the sample is illuminated at a wavelength of light that results in a detectable optical response and observed with a means for detecting the optical response.
  • the optical response may be colorimetric or luminescent. That is, the free rhodamine compound strongly absorbs light in the visible region, and protease activity may be detected/quantified on that basis. Alternatively, a luminescence response may be used to detect/quantify protease activity.
  • the illumination source typically is selected so that efficient excitation of the free compound is achieved. Because of the high intensity luminescence of the cleavage products in the visible wavelengths, the protease substrates of the invention are particularly well suited for detection of protease activity in biological samples.
  • useful illumination sources include ultraviolet or visible wavelength emission lamps, arc lamps, or lasers. These illumination sources are optionally integrated into spectrophotometers, laser scanners, fluorescence microplate readers, standard or mini fiuorometers, flow cytometers, fluorescence microscopes, or chromatographic detectors.
  • the luminescence emission is optionally detected by visual inspection or by use of any of the following devices: CCD cameras, video cameras, photographic film, laser scanning devices, fiuorometers, photodiodes, quantum counters, epifluorescence microscopes, scanning microscopes, flow cytometers, fluorescence microplate readers, any of which may optionally incorporate photomultiplier tubes to enhance the detectable luminescence signal.
  • the luminogenic compositions of the invention facilitate detection of protease activity, whether intracellular or extracellular.
  • the compounds of the invention are particularly well suited for high-throughput screening techniques, particularly those involving automated methods and small sample volumes.
  • the observation of a detectable optical response in the sample is typically correlated with the appearance of free rhodamine luminophore in the sample, and therefore the presence of an appropriate protease enzyme.
  • the correlation typically is accomplished by comparison of the luminescence response to a standard, or calibration, curve.
  • the standard curve is generated according to methods known in the art using various and known enzyme activity levels, or by comparison with a reference dye or dyed particle that has been standardized versus a known enzyme activity.
  • the invention provides methods for detecting the activity of a protease enzyme.
  • the methods involve contacting the protease with one or more of the protease substrates described herein.
  • the "contacting" is in a histological section or in a cell suspension or culture derived from a biological sample selected from the group consisting of a tissue, blood, urine, saliva, or other biofluid, lymph, biopsy.
  • the detection method can include a method selected from the group consisting of fluorescence microscopy, fluorescence microplate reader, flow cytometry, fluorometry, and absorption spectroscopy.
  • any of the compositions described above may be used in a method for detecting protease activity in a sample.
  • the sample may be a sample of "stock" protease, such as is used in research or industry, or it may be a biological sample.
  • this invention provides for a method of detecting protease activity in a sample by contacting the sample with any of the compositions described above and then detecting a change in luminescence of the luminogenic composition where an increase in luminescence indicates protease activity.
  • the sample may be a biological sample which may include biological fluids such as sputum or blood, tissue samples such as biopsies or sections (including tumor biopsies), and cell samples either as biopsies or in cells or tissues in culture, or tissue sections where the section is unimbedded and unfixed. Particularly preferred samples are tissue sections, cultured cells, cultured tissues, and the like.
  • the present invention provides methods for utilizing the luminogenic protease substrates to detect protease activity in a variety of contexts.
  • the present invention provides for a method of using the luminogenic substrates to verify or quantify the protease activity of a stock solution of a protease used for experimental or industrial purposes. Verification of protease activity of stock protease solutions before use is generally recommended as proteases often exhibit diminished activity over time (e.g., through self-hydrolysis) or show varying degrees of activation when activated from zymogen precursors.
  • Assaying for protease activity of a stock solution simply requires adding a quantity of the stock solution to a luminogenic protease substrate of the present invention and measuring the subsequent increase in luminescence or decrease in excitation in the absorption spectrum.
  • the stock solution and the luminogenic substrate may also be combined and assayed in a "digestion buffer" that optimizes activity of the protease.
  • Buffers suitable for assaying protease activity are well known to those of skill in the art.
  • a buffer will be selected whose pH corresponds to the pH optimum of the particular protease.
  • a buffer particularly suitable for assaying elastase activity consists of 50 mM sodium phosphate, 1 mM EDTA at pH 8.9.
  • the measurement is most easily made in a fluorometer, an instrument that provides an "excitation" light source for the luminophore and then measures the light subsequently emitted at a particular wavelength. Comparison with a control substrate solution lacking the protease provides a measure of the protease activity.
  • the activity level may be precisely quantified by generating a standard curve for the protease/substrate combination in which the rate of change in luminescence produced by protease solutions of known activity is determined. While detection of the luminogenic compounds is preferably accomplished using a fluorometer, detection may by a variety of other methods well known to those of skill in the art.
  • detection may be simply by visual inspection of luminescence in response to excitation by a light source, such as through a fluorescence microscope. Detection may also be by means of an image analysis system utilizing a video camera interfaced to an digitizer or other image acquisition system. Detection may also be by visualization through a filter as under a fluorescence microscope. The detected signal may also be recorded on photographic film or using a video analysis system. The signal may be quantified on a realtime basis using either an image analysis system or a photometer.
  • a basic assay for protease activity of a sample may involve suspending or dissolving the sample of interest in a buffer (at the pH optima of the particular protease being assayed), adding to the buffer one of the luminogenic protease substrates of the present invention, and monitoring the resulting change in luminescence using a spectrofluorometer.
  • the spectrofluorometer may be set to excite the free luminophore at the excitation wavelength of the luminophore and to detect the resulting luminescence at the emission wavelength of the luminophore
  • the rhodamine-based substrates of the invention may display sensitivity, specificity and selectivity in their interactions with particular protease enzymes.
  • the specificity exhibited by many proteases may depend to a large extent upon the interaction of subsite amino acids in the protease active site with extended amino acid residues in the peptide substrate. This interaction may be characterized through the use of synthetic substrates, by observing variations in the specificity constant upon substituting or altering a single residue in the substrate peptide sequence.
  • the present invention provides for methods of detecting protease activity in isolated biological samples. This may be determined by simply contacting the sample with a luminogenic protease substrate of the present invention and monitoring the change in luminescence of the substrate over time.
  • the sample may be suspended in a "digestion buffer" as described above.
  • the sample may also be cleared of cellular debris, e.g., by centrifugation before analysis.
  • the invention also provides for a method of detecting in situ protease activity in histological sections.
  • This method of detecting protease activity in tissues offers significant advantages over previous methods (e.g., specific stains, antibody labels, etc.) because, unlike simple labeling approaches, in situ assays using the protease substrates indicate actual activity rather than simple presence or absence of the protease.
  • Proteases are often present in tissues in their inactive precursor (zymogen) forms which are capable of binding protease labels. Thus traditional labeling approaches provide no information regarding the physiological state, via protease activity, of the tissue.
  • the in situ assay method generally includes providing a tissue section (preferably a frozen section), contacting the section with one of the luminogenic protease substrates of the present invention, illuminating the section, and detecting any resulting optical signal.
  • the sections are preferably cut as frozen sections as fixation or embedding may destroy protease activity in the sample. Visualization may be accomplished utilizing a fluorescence microscope.
  • the luminogenic substrate may be introduced to the tissue sections in a number of ways.
  • the luminogenic protease substrate may be provided in a buffer solution, as described above, which is applied to the tissue section.
  • the luminogenic protease substrate may be provided incorporated in a semi-solid matrix, such as agar or other gel, that is then spread over the tissue sample and helps hold moisture in the sample while providing a signal in response to protease activity.
  • the luminogenic protease substrate may also include a conjugated substance that is a polymer, such as a plastic film, which may be used in procedures similar to the development of Western Blots. The plastic film may be placed over the tissue sample on the slide and the luminescence resulting from cleaved substrate molecules may be viewed in the sample tissue under a microscope.
  • tissue sample should be incubated for a period of time to allow the endogenous proteases to cleave the luminogenic protease substrates of the invention. Incubation times may range from a few minutes to several hours at temperatures up to and including 37 °C.
  • This invention further provides for a method of detecting in situ protease activity of cells in culture or cell suspensions derived from tissues, biopsy samples, or biological fluids (e.g., saliva, blood, urine, lymph, plasma, etc.).
  • the cultured cells are grown either on chamber slides or in suspension and then transferred to histology slides by cytocentrifugation.
  • the cell suspensions are prepared according to standard methods and transferred to histology slides.
  • the slide is washed with phosphate buffered saline and coated with a semi-solid matrix or a solution containing the luminogenic protease substrate.
  • the slide is incubated at 37 °C for the time necessary for the endogenous proteases to cleave the protease substrate.
  • the slide is then examined under a fluorescence microscope equipped with the appropriate filters as described above.
  • the cells are incubated with the protease substrates at 37 °C, then washed with buffer and transferred to a glass capillary tube and examined under a fluorescence microscope.
  • the cells with the luminogenic substrate are simply diluted with buffer after 37 °C incubation and analyzed.
  • E. Protease binding site and conformation determining regions The protease binding site and conformation determining regions form a contiguous amino acid sequence that is recognized and cleaved by a particular protease. It is well known that various proteases cleave peptide bonds adjacent to particular amino acids.
  • trypsin cleaves peptide bonds following basic amino acids such as arginine and lysine and chymotrypsin cleaves peptide bonds following large hydrophobic amino acid residues such as tryptophan, phenylalanine, tyrosine and leucine.
  • the serine protease elastase cleaves peptide bonds following small hydrophobic residues such as alanine.
  • proteases will not cleave every bond in a protein that has the correct adjacent amino acid. Rather, the proteases are specific to particular amino acid sequences which serve as recognition domains for each particular protease. Without being bound by a particular theory, it is believed that a specific protease's preference for a particular cleavage site over many other potential sites in a folded globular protein may be largely determined by the potential cleavage sites' amino acid sequences and also their conformation and conformational flexibility.
  • ribonuclease-S a noncovalent complex consisting of two polypeptide chains
  • subtilisin a protease called subtilisin
  • Staphylococal nuclease-T a two chain noncovalent complex, Staphylococal nuclease-T, from single chain Staphylococcal nuclease by trypsin digestion.
  • Another example of a specific protease's preference for one substrate over others is the human fibroblast- type collagenase.
  • This protease prefers type I over type III soluble collagen even though both substrates contain the same collagenase sensitive Gly-Ile or Gly-Leu bonds (see, Birkedal-Hansen et. al. Crit. Rev. in Oral Biology and Medicine 1993, 4,197-250).
  • protease substrate sequences and peptide inhibitors of proteases possess amino acid sequences that are recognized by the specific protease they are cleaved by or that they inhibit.
  • substrate and inhibitor sequences provide the basic sequences suitable for use in the protease recognition region.
  • a large number of protease binding region protease substrates and inhibitor sequences suitable for use as protease binding domains in the compositions of this invention are known (see for example, U.S. Patent No. 6,335,429 and U.S. Patent No. 6,342,611), can be used for this invention.
  • protease substrates or inhibitor sequences including variations and modifications of previously disclosed sequences, may be used in the present invention.
  • kits for the detection of protease activity in samples comprise one or more containers containing the luminogenic protease substrates of the present invention.
  • the substrates may be provided in solution or bound to a solid support.
  • the kits may contain substrate solutions or substrate "dipsticks", blotters, culture media, and the like.
  • the kits may also contain substrate cartridges for use in automated protease activity detectors.
  • the kits additionally may include an instruction manual that teaches the method and describes use of the components of the kit.
  • kits may also include additional reagents, including but not limited to buffering agents, luminescence calibration standards, enzymes, enzyme substrates, protease inhibitors, nucleic acid stains, labeled antibodies, culture media, disposable cuvettes, and/or other additional luminescence detection reagents, and the like to aid the detection of protease activity utilizing the luminogenic protease substrates of the present invention.
  • additional reagents including but not limited to buffering agents, luminescence calibration standards, enzymes, enzyme substrates, protease inhibitors, nucleic acid stains, labeled antibodies, culture media, disposable cuvettes, and/or other additional luminescence detection reagents, and the like to aid the detection of protease activity utilizing the luminogenic protease substrates of the present invention.
  • kits optionally may include chemically reactive forms of the substrates to permit a user to label substances of interest and develop individual assays.
  • the kits may include conjugates of the desired substrate that are selected specifically for a particular assay, typically where the conjugated substance is a member of a specific binding pair.
  • the compounds of the invention optionally are present in pure form as a lyophilized solid, or as a concentrated stock solution, or in a prediluted solution ready for use in the appropriate assay.
  • the kit is designed for use in an automated and/or high-throughput assay, and so is designed to be fully compatible with microplate readers, microfluidic methods, and/or other automated high-throughput methods.
  • Kits may additionally or alternatively comprise any of the substrates described herein (e.g., nucleic acid based substrates, oligosaccharide substrates, lipid substrates, etc). In this instance the kit will facilitate detection of the particular activities/compounds/interactions for which the particular substrate backbone is a substrate or binding agent.
  • the kit will facilitate detection of the particular activities/compounds/interactions for which the particular substrate backbone is a substrate or binding agent.
  • the peptide synthesis may be performed using Fmoc synthesis chemistry.
  • the side chains of Asp, Ser, Thr and Tyr are preferably protected using t- Butyl protecting groups, while the side chain of the Cys residue is protected using S- trityl and S-t-butylthio protecting groups.
  • Lys residues are preferably protected using t-Boc, Fmoc and/or 4-methyltrityl protecting groups. Many appropriately protected amino acid reagents are commercially available. The use of multiple protecting groups allows selective deblocking and coupling of a desired luminophore to any particular desired side chain.
  • t-Boc deprotection is accomplished using trifluoroacetic acid (TFA) in dichloromethane
  • Fmoc deprotection is accomplished using 20% (v/v) piperidine in DMF or N-methylpyrolidone
  • 4- methyltrityl deprotection is accomplished using 1 to 5% (v/v) TFA in water or 1% TFA and 5% truisopropylsilane in DCM
  • S-t-butylthio deprotection is accomplished in aqueous mercaptoethanol (10%)
  • t-butyl and t-boc and S-trityl deprotection is accomplished using TFA:phenol:water:thioanisol:ethanedithiol (85:5:5:2.5:2.5)
  • t- butyl and t-Boc deprotection is accomplished using TFA :phenol: water (95:5:5).
  • TFA trifluoroacetic acid
  • the peptide components of the luminogenic protease substrates of the present invention may be synthesized utilizing recombinant DNA technology.
  • a DNA molecule encoding the desired amino acid sequence may be synthesized chemically using any of a variety of methods known to those of skill in the art, including the solid phase phosphoramidites method described by Beaucage and Carruthers, Tetrahedron Lett. 22, 1859-1862 (1981), the triester method according to Matteucci, et al., J. Am. Chem. Soc, 103,3185 (1981), or by other known methods. It is preferred that the DNA be synthesized using standard ⁇ -cyanoethyl phosphoramidites on a commercially available DNA synthesizer using standard protocols.
  • the oligonucleotides may be purified, if necessary, by techniques well known to those of skill in the art. Typical purification methods include, but are not limited to gel electrophoresis, anion exchange chromatography (e.g., Mono-Q column, Pharmacia-LKB, Piscataway, N.J., USA), or reverse phase high performance liquid chromatography (HPLC). Methods of protein and peptide purification are well- known. For a review of standard techniques see, Methods in Enzymology Volume 182: Guide to Protein Purification, M. Deutscher, ed. (1990), pp. 619-626.
  • the oligonucleotides may be converted into double stranded DNA either by annealing with a complementary oligonucleotide or by polymerization with a DNA polymerase.
  • the DNA may then be inserted into a vector under the control of a promoter and used to transform a host cell so that the cell expresses the encoded peptide sequence.
  • Standard methods of cloning and expression of peptides are well- known. See, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual (2 nd Ed., Vols. 1-3, Cold Spring Harbor Laboratory (1989)), Methods in Enzymology,
  • the luminogenic protease substrates of the present invention are preferably prepared by first preparing a mono-amino acid-substituted rhodamine-MPL compound, and then coupling the remaining required amino acids using standard peptide synthesis methods in the desired sequence.
  • the desired compound may be prepared by coupling the Rhl 10-MPL compound with a complete peptide sequence in a single step (see for example, Example 10). The latter procedure may exhibit a lower yield than the corresponding stepwise synthesis.
  • the assays of the invention optionally may be performed using apparatus, methods, and or compositions described in the various patents and patent applications listed above under Cross-References and incorporated herein by reference.
  • the apparatus include luminescence detectors and sample holders such as microplates, among others.
  • the methods include photoluminescence methods, such as luminescence intensity, among others.
  • the compositions include various energy transfer donors and acceptors, among others. Examples
  • Example 10 Two-step preparation of Compound 8.
  • Compound 3 (0.9 g, 1.46 mmol) is dissolved in anhydrous DMF (40 mL).
  • Compound 1 is treated with a protected Asp-Glu-Val-Asp tetrapeptide (Ac- Asp(O t Bu)-Glu(O t Bu)-V-(O-Boc-D)-OH) in a manner analogous to that described in Example 2 to give the desired product.
  • Compound 1 is treated with the protected Asp-Glu-Val-Asp tetrapeptide Cbz- Asp(O t Bu)-Glu(O t Bu)-V-(O-Boc-D)-OH in a manner analogous to that described in Example 2 to give the desired product.
  • Compound 1 is treated with protected alanine (N-Fmoc-Ala-OH) in a manner analogous to that described in Example 2 to give the desired product.
  • Compound 15 is coupled with a protected alanine (N-Cbz-Ala-OH) using a method similar to that described in Example 2 to give the desired product.
  • Example 18 Compound 3 is deprotected in a manner similar to that described in Example 9 to give the desired product.
  • Example 18 The luminogenic protease substrates of the invention provide a strong signal upon protease digestion.
  • the degree of cleavage is determined by assaying for the appearance of substrate cleavage products in the presence of a protease.
  • protease substrate substituted with an appropriate peptide (as partially listed in Table 1) is dissolved in a buffer consisting of the appropriate salts and other additives needed to preserve enzyme activity.
  • a protease such as elastase, trypsin and caspases etc
  • the solution is incubated.
  • the solution is then analyzed by a luminescence instrument such as microscope, microplate reader, or a spectrophotometer.
  • the solution is analyzed by HPLC before and after the addition of the protease.
  • the digestion is carried out at 37 °C.
  • the HPLC-separated components are monitored either via absorption or luminescence.
  • Figure 3 shows the fluorescence emission spectrum of Compound 9 (Ac-DEVD-Rhl 10-MPL) (a) before and (b) after addition of caspase-3, a representative protease.
  • Example 19 Uptake and retention of MLP-Rhl 10-PP derivatives in live cells.
  • Jurkat cells are placed in 5 mL of HBSS medium containing 1-25 ⁇ M of the desired rhodamine 110-based protease substrate. The cells are incubated for varying times at 37 °C in a CO incubator, recovered by centrifugation, and washed in 50 mL of ice-cold medium. The cells are then re-centrifuged and the final pellet is resuspended in 50 ⁇ L of fresh medium. Aliquots of each cell suspension are placed on microshdes and viewed on a Nikon inverted microscope with epifluorescent illumination.
  • the cells exhibit good staining by the rhodamine-based enzymatic reaction products. Other cells are treated similarly as described for the Jurkat cells with appropriate modifications.
  • Example 20 Susceptibility of the peptide-rhodamine 110-MPL derivatives to protease activity.
  • Peptide-rhodamine 110-MPL activities as synthetic substrates for proteases are measured in a luminometric enzyme assay.
  • Some enzymes are commercially available, and the commercially unavailable enzymes are prepared by expressing
  • Example 21 Cleavage of Compound 9 by recombinant human caspase-3.
  • Compound 9 is incubated with various concentrations of purified active human recombinant caspase-3 (Sigma) at 37 °C.
  • the caspase-3 is prepared in PBS buffer containing 0.1 % BSA. 100 ⁇ L of diluted caspase-3 are transferred into a 96- well black microplate (with clear bottoms) into each well of which an equal volume of 50 ⁇ M Compound 9 in 2X reaction buffer (20 mM HEPES buffer, pH 7.4, 0.2% CHAPS, 4 mM EDTA, and 10 mM DTT) is added.
  • the enzymatic reaction kinetics are measured using excitation at 485 nm and detecting the luminescence emission at 525 nm for 1 hr at 20 second intervals using a FLEXstationTM fluorescence microplate reader with integrated microfludics system (Molecular Devices Corporation).
  • Figure 4 shows the time-dependent luminescence increase after the addition of 1 unit of caspase-3.
  • the enzyme concentrations (from the bottom curve to the top curve) are 0, 0.61, 1.25, 2.50, 5.00 and 10.00 ng/well, respectively.
  • Example 22 A comparison of Compound 9 with bis-(Acetyl-DEVD)- rhodamine 110 in the detection of recombinant human caspase-3.
  • the caspase-3 assay used is similar to that described in Example 21. 100 ⁇ L of purified active human recombinant caspase-3 (10 ng/well, Sigma) in PBS buffer containing 0.1 % BSA is treated with an equal volume of 50 ⁇ M Compound 9 or (Ac-
  • Example 23 Cleavage of Compound 9 by apoptotic cells.
  • a supply of JurKat cells at a concentration of about 100,000/well (100 ⁇ L ) are plated into a 96-well black plate (with clear bottom) in RPMI medium containing
  • Example 24 Detection of cell apoptosis using a microplate reader.
  • One of the earliest and most consistently observed features of apoptosis is the expression of a series of cytosolic proteases, the caspases, which cleave protein substrates and lead to apoptotic morphology.
  • Caspase-3 also called appopain or CPP32, has been identified to be a key member of this caspase family of proteases. (See, Abu-Qare, A. W. and M. B.
  • Both the control and induced cells are then incubated with an equal volume of 50 ⁇ M Compound 9 in 2X reaction buffer (20 mM HEPES buffer, pH 7.4, containing 0.2% CHAPS, 4 mM EDTA, and 10 mM DTT) at room temperature for 30 min.
  • the luminescence is measured using a FLEXstationTM fluorescence microplate reader using excitation at 485 nm and emission detection at 525 nm.
  • Figure 7 shows the cell number response of caspase 3 activity in the JurKat cells.
  • Figure 8 shows the dose response of camptothecin on the JurKat cell apoptosis.
  • the Z factors are 0.51, 0.88, 0.8, 0.86, 0.76, and 0.83 corresponding to camptothecin doses from 0.1 to 30 ⁇ M.
  • Figure 9 shows time course response of camptothecin- induced JurKat cell apoptosis detected by Compound 9.
  • Example 25 The comparison of Compound 9 with bis-(Ac-DEND)- rhodamine 110 for detection of cell apoptosis.
  • JurKat cells at the density of 100,000 cells/well (100 ⁇ L ) are seeded into a 96-well black plate (with clear bottom).
  • the cells are treated with camptothecin (2 ⁇ M ) for 6 hours at 37 °C in a 5% CO 2 incubator to induce apoptosis, and the untreated cells are used as a 'control'.
  • Both the control and induced cells are then incubated with an equal volume of 50 ⁇ M Compound 9 or bis-(Ac-DEND)- rhodamine 110 in 2X reaction buffer (20 mM HEPES buffer, pH 7.4, containing 0.2% CHAPS, 4 mM EDTA, and 10 mM DTT) at room temperature for 30 min.
  • the incubations are performed either in the presence of Ac-DEVD-CHO, a caspase-3 inhibitor (20 ⁇ M) or in the absence of the inhibitor.
  • the resulting luminescence is measured using a FLEXstationTM fluorescence microplate reader using excitation at
  • Example 26 Detection of cell apoptosis by luminescence microscopy using the protease substrates of the invention.
  • caspase substrates of the invention detect caspase activation in intact cells is tested using apoptotic HL-60 and Jurkat cells. These whole-cell assays are carried out in two stages: 1) induction of apoptosis, and 2) incubation with the selected substrate. For HL-60 cells, apoptosis is induced by treatment with 10 ⁇ g/mL vinblastine for 4 hours. Control samples are treated with
  • DMSO DMSO for Jurkat cells
  • apoptosis is induced by treatment with 500 ng/mL agonistic antiFas antibody for 2 hours.
  • Control samples are treated with PBS.
  • the cells are incubated with 50 ⁇ M Compound 9 in caspase assay buffer (40 mM PIPES, pH 7.4; 100 mM NaCl; 10% sucrose; 1 mM EDTA; 10 mM DTT).
  • caspase assay buffer 40 mM PIPES, pH 7.4; 100 mM NaCl; 10% sucrose; 1 mM EDTA; 10 mM DTT.
  • the cells are than transferred to a glass microslide and viewed using epifluorescent illumination on a Nikon inverted microscope. It is observed that drug- treated cells exhibit higher luminescence than DMSO-treated cells (control).
  • HL-60 cells treated with 50 ⁇ M the caspase-3 inhibitor Ac-DEVD-CHO show reduced luminescence signal, indicating that the staining observed in the treated cells is due to caspase-mediated cleavage.
  • Jurkat cells induced to undergo apoptosis by antiFas also show intense staining when incubated with Compound 9 while control cells showed only minimal staining.
  • Example 27 Cleavage of Ac-IETD-Rhl 10-MPL by caspases 3, 6. 7. and 8.
  • a protease substrate of the invention is prepared having an acetylated tetrapeptide side chain having the sequence Ile-Glu-Thr-Asp (or IETD, SEQ ED NO.
  • the caspase assays are carried out at 37 °C in 96-well plates in 100 ⁇ L of buffer containing recombinant human caspase, 5 ⁇ M of Ac-IETD-Rhl 10-MPL and caspase assay buffer (50 mM PIPES, pH 7.2; 100 mM NaCl; 10% sucrose; 0.1% CHAPS; 1 mM EDTA; 10 mM DTT).
  • the luminescence of the samples is determined on a Gemini fluorescence microplate reader (Molecular Devices Corporation) using excitation and emission wavelengths of 490 nm and 550 nm respectively.
  • control samples (where the corresponding enzyme is omitted) are used to correct the background fluorescence of non-specific hydrolysis of the substrate.
  • caspase inhibitors such as Ac-DEVD-CHO (Acetyl-L-Aspartyl-L-Glutamyl-L-Valyl-L-Aspart-1-al; SEQ ID NO. 22) and Ac- IETD-CHO (Acetyl-L-Isoleucyl-L-Glutamyl-L-Threonyl-L-Aspart-1-al; SEQ ID NO. 23)are used to further confirm the specificity of the substrate. It is observed that Ac- IETD-Rhl 10-MPL is cleaved by caspase 8.
  • Example 28 Cleavage of Cbz-AA-Rhl 10-MPL and Cbz-AAAA-Rhl 10- MPL by elastase. Approximately 1 microgram of the substrates Cbz-AA-Rhl 10-MPL or Cbz-
  • AAAA-Rhl 10-MPL is dissolved in a buffer (pH 8.9) consisting of 50 mM sodium phosphate and 1 mM EDTA. To this solution is added 1 unit of elastase, and the samples are incubated. The enzymatic reaction is followed using a fluorescence microplate reader substantially as described in Example 24 above.
  • Example 29 Flow cytometric analysis of cells incubated with apoptosis- related protease substrates.
  • the substrate of the invention is present in a concentration of 10 ⁇ M in RPM 11640 medium containing from 4% to 10% fetal calf serum.
  • Cell densities during incubation with the chosen substrates ranged from 50,000 cells/mL to 4,000,000 cells/mL.
  • Incubation times are from 30 min to 3 hr at 37 °C, and incubation volumes are from 50 ⁇ L to 2 mL.
  • cell suspensions are diluted 10-fold with ice cold Hank's Buffered Saline Solution (HBSS) and then filtered through a nylon fabric sheet.
  • HBSS Hank's Buffered Saline Solution
  • This filtered cell suspension is then subjected to fluorescence-based flow cytometric analysis using a 488 nm excitation source. Control cells without substrate incubation and the sample with the greatest expected luminescence signals are used to set the instrument detector parameters. A small amount of background luminescence would be expected from non-specific hydrolysis or the intact substrate. Signals from the cells that had been activated with 1 ⁇ g/ml of ant-Fas antibody, CH11 clone for 1 to 6 hours indicated an increase in peak channel number. A large increase in luminescence intensity is observed.
  • Example 30 Screening for drugs that stimulate the caspase cascade.
  • Drugs that stimulate the caspase cascade in the absence of Fas ligand or camptothecin may be useful, for example, as anti-cancer chemotherapeutic agents.
  • the assay procedures substantially described in Examples 19-27 may be used to screen for drugs that stimulate the caspase cascade by carrying out the assay under similar conditions as in the above examples, except employing a known or unknown compound with known or unknown anti-cancer or anti-tumor activity in place of camptothecin or Fas ligand reagent.
  • Example 31 Screening for drugs that inhibit or potentiate the caspase cascade.
  • Drugs that inhibit the caspase cascade may be useful in treating degenerative and other diseases caused by or associated with an inadequate activation of the caspase cascade.
  • Drugs that potentiate the action of another caspase stimulator, such as Fas ligand or an anti-cancer drug or agent may be suitable to treat cancers or tumors caused by or associated with an inappropriate function of the caspase cascade.
  • the assays and reagents described in this invention may be used to screen for drugs that may inhibit or potentiate the caspase cascade in cells by performing the assay substantially as described in Examples 19-27 using camptothecin, Fas ligand, or any other agent that sufficiently stimulates the caspase cascade or other apoptosis pathway.
  • Such an assay may include the presence of a test substance that may inhibit, potentiate, or acts synergistically with, the action of the first agent that induced apoptosis or caspase cascade.
  • Example 32 Evaluation of potential chemotherapeutic treatments.
  • the luminescence assays described in this invention permit chemosensitivity or drug resistance testing of cancer or tumor cells or tissue samples taken from individual cancer or tumor patients.
  • a luminescence assay using a cancer cell or tissue sample taken from a patient may be conducted substantially as described in Examples 19-27.
  • a drug having a known or unknown chemotherapeutic activity may therefore be tested for its capacity to stimulate the caspase cascade, potentially providing information useful in designing an optimal chemotherapeutic drug treatment regimen for the patient.
  • Example 33 Use of PP-Rhl 10-MPL in high throughput screening of drugs.
  • the protease substrates of the invention may be useful for high throughput screening of drugs. Such assays are typically performed similarly to those described in Examples 21, 23 and 24, while typically utilizing a much smaller volume and employing automated methods. Such assays may be run in a high density multi-well microplate (such as 384-well or 1536-well plate), or a microarray device suitable for high-throughput screening.
  • a high density multi-well microplate such as 384-well or 1536-well plate
  • Example 34 Reduction of extracellular and/or background fluorescence:
  • the assays of the invention optionally may be performed using systems for reducing extracellular and/or background luminescence, including separating layers and/or masking compounds. These systems may be particularly useful in assays of intracellular protease activity, where they may be used to reduce detection of luminescence from free rhodamine dyes that have leaked from the cell interior into the extracellular medium.
  • a separating layer generally comprises any material that separates labeled cells from the majority of the extracellular medium (typically by being positioned between the labeled cells and the majority of the extracellular medium) and that reduces detection of light from the majority of the extracellular medium.
  • the separating layer may reduce the detection of undesired light using any suitable mechanism, including (1) absorbing and/or reflecting excitation light before it excites extracellular luminophores, and/or (2) absorbing and/or reflecting luminescence emitted by extracellular luminophores.
  • Exemplary separating layers may include (1) a thin film or coating of metal, beads, or other absorbent and/or reflective materials, which typically is permeable to the extracellular medium, and/or (2) a sample container insert that displaces medium away from the cells, which typically is impermeable to the extracellular medium.
  • Exemplary separating layers are disclosed in the following materials, which are incorporated herein by reference: U.S. Patent No. 5,601,997, issued February 11, 1997; and PCT Patent Application Serial No. PCT/EP97/02662, filed May 23, 1997.
  • a masking (or photon-reducing) compound generally comprises any composition such as a molecule or particle that reduces the amount of light detected from luminescent materials in the extracellular medium.
  • the masking compound may reduce the amount of light using any suitable mechanism, including (1) absorbing excitation light before it excites extracellular luminophores, (2) reducing and/or quenching the luminescence of the extracellular luminophores (e.g., by reducing their extinction coefficients and/or quantum yields), and/or (3) absorbing luminescence emitted by the extracellular luminophores, among others.
  • Exemplary masking compounds may include (1) binding partners, such as antibodies, (2) paramagnetic ions, such as Mn 2+ , Co 2+ , or Cu 2+ , (3) quenchers, such as static and dynamic quenchers, (4) energy transfer partners, such as complementary acceptors, and/or (5) dyes having overlapping spectra, among others.
  • Dyes having overlapping spectra may include (1) acid dyes (e.g., sulphan blue, acid violet, acid red, amido black, brilliant blue R, azocarmine G, xylidine P.
  • the masking compound includes one or more of
  • Acid Blue 45 Acid Blue 92, Acid Blue 93, Acid Green 25, Acid Red 106, Acid Red 112 (Ponceau S), Acid Red 40, Acid Violet 5, Acid Violet 7, Alcian Blue 8GX, Amaranth, Brilliant Black BN, Brompyrogallol Red, Direct Blue 71, Direct Red 75, Direct Violet 51, Erioglaucine (Food Dye Blue), Erythrosin B, Gallocyanine, Hydroxy Naphthol Blue, Indigo Carmine, Malachite Green, Phenol Red, Potassium Ludigotrisulfonate, QSY-7, Reactive Black 5, Reactive Blue 2, Sufonazo III, and Violamine R.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
EP03729139A 2002-05-24 2003-05-23 Luminogene proteasesubstrate Withdrawn EP1517997A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38336302P 2002-05-24 2002-05-24
US383363P 2002-05-24
PCT/US2003/016530 WO2003099780A2 (en) 2002-05-24 2003-05-23 Luminogenic protease substrates

Publications (2)

Publication Number Publication Date
EP1517997A2 EP1517997A2 (de) 2005-03-30
EP1517997A4 true EP1517997A4 (de) 2006-11-15

Family

ID=29584553

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03729139A Withdrawn EP1517997A4 (de) 2002-05-24 2003-05-23 Luminogene proteasesubstrate

Country Status (3)

Country Link
EP (1) EP1517997A4 (de)
AU (1) AU2003234638A1 (de)
WO (1) WO2003099780A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047245A2 (en) 2003-11-14 2005-05-26 Wisconsin Alumni Research Foundation Fluorescence assays with improved blocking groups
WO2009045104A1 (en) * 2007-10-05 2009-04-09 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Method for diagnosing presymptomatic organ transplant rejection
US8460862B2 (en) * 2009-03-11 2013-06-11 Marker Gene Technologies Enzyme substrates for visualizing acidic organelles
JP5795963B2 (ja) * 2010-01-13 2015-10-14 国立大学法人 東京大学 がん診断薬
FR2978163B1 (fr) * 2011-07-22 2013-08-30 Stago Diagnostica Utilisation d'un substrat dans une methode pour mesurer l'activite des enzymes proteolytiques disponibles
FR2978164B1 (fr) * 2011-07-22 2013-08-30 Stago Diagnostica Utilisation d'un substrat dans une methode pour mesurer l'activite des enzymes proteolytiques
WO2014013272A1 (en) 2012-07-19 2014-01-23 Kingston University Higher Education Corporation Rhodamine based fluorescent probe for coagulase activity and detection of coagulase producing bacterial strains
US10383956B2 (en) 2014-07-11 2019-08-20 The University Of Tokyo Fluorescent probe for detecting dipeptidyl peptidase IV
JP6881294B2 (ja) * 2015-02-27 2021-06-02 国立大学法人 東京大学 カルパイン活性検出蛍光プローブ
CN109438319B (zh) * 2018-09-17 2022-05-10 湖北大学 一种检测亮氨酸氨肽酶的化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004914A1 (en) * 1998-07-21 2000-02-03 Cytovia, Inc. Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
WO2000064988A1 (en) * 1999-04-23 2000-11-02 Molecular Probes, Inc. Xanthene dyes and their application as luminescence quenching compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640893A (en) * 1983-10-28 1987-02-03 University Of Illinois Novel rhodamine derivatives as fluorogenic substrates for proteinases
US4557862A (en) * 1983-10-28 1985-12-10 University Patents, Inc. Rhodamine derivatives as fluorogenic substrates for proteinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004914A1 (en) * 1998-07-21 2000-02-03 Cytovia, Inc. Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
WO2000064988A1 (en) * 1999-04-23 2000-11-02 Molecular Probes, Inc. Xanthene dyes and their application as luminescence quenching compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG Z-Q ET AL: "N-DEVD-N'-morpholinecarbonyl-rhodamine 110: novel caspase-3 fluorogenic substrates for cell-based apoptosis assay", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 9, 2005, pages 2335 - 2338, XP004851625 *

Also Published As

Publication number Publication date
WO2003099780A3 (en) 2004-04-01
EP1517997A2 (de) 2005-03-30
WO2003099780A2 (en) 2003-12-04
AU2003234638A8 (en) 2003-12-12
AU2003234638A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
US6893868B2 (en) Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
US7879574B2 (en) Compositions for the detection of enzyme activity in biological samples and methods of use thereof
US6335429B1 (en) Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
US5605809A (en) Compositions for the detection of proteases in biological samples and methods of use thereof
US20140179901A1 (en) Peptide Conjugates and Fluorescence Detection Methods for Intracellular Caspase Assay
JP2001519368A (ja) 新規の蛍光レポーター分子、およびカスパーゼのアッセイを含むその適用
US20030166028A1 (en) Peptide biosensors for anthrax protease
EP1497452B1 (de) Verfahren zur bestimmung von enzym aktivität
US7312302B2 (en) Compositions for the detection of enzyme activity in biological samples and methods of use thereof
EP1517997A2 (de) Luminogene proteasesubstrate
AU7368800A (en) Compositions for the detection of enzyme activity in biological samples and methods of use thereof
Wysocka et al. Future of protease activity assays
US20090023200A1 (en) Particle for detecting enzyme activity, method for detecting the enzyme activity and enzyme activity detection device by the use thereof
Lozanov et al. Peptide substrate for caspase-3 with 2-aminoacridone as reporting group
US20240272146A1 (en) Chromogenic and fluorogenic compounds and their use for biological detection
Sato Development of Novel Doubly Labelled Peptide Probes with Identical Fluorophores for Protease Activity Measurement
AU2006200291A1 (en) Compositions for the detection of enzyme activity in biological samples and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041222

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061018

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061201